About: Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus
Creator	Aga, Miho Ariyasu, Harumi Ariyasu, Toshio Fukuda, Shigeharu Nagatomo, Daiki Ohta, Tsunetaka Taniai, Madoka Taniguchi, Mutsuko
Source	Medline; PMC
abstract	We encapsulated tumor necrosis factor-α (TNF-α), a major proinflammatory cytokine, into cholesteryl pullulan (CHP) to prepare TNF/CHP nanoparticles. In this report, we describe the immune-enhancing capability of the nanoparticles to act as a vaccine adjuvant. TNF/CHP nanoparticles showed excellent storage stability and enhanced host immune responses to external immunogens. The nanoparticles were effective via the nasal route of administration for inducing systemic IgG(1) as well as mucosal IgA. We applied the nanoparticles in a model experimental influenza virus infection to investigate their adjuvant ability. TNF/CHP nanoparticles combined with a conventional split vaccine protected mice via nasal administration against a lethal challenge of A/PR/8/34 (H1N1) influenza virus. Mechanistic studies showed that the nanoparticles enhanced antigen uptake by dendritic cells (DCs) and moderately induced the expression of inflammation-related genes in nasopharynx lymphoid tissue (NALT), leading to the activation of both B and T cells. Preliminary safety study revealed no severe toxicity to TNF/CHP nanoparticles. Slight-to-moderate influences in nasal mucosa were observed only in the repeated administration and they seemed to be reversible. Our data show that TNF/CHP nanoparticles effectively enhance both humoral and cellular immunity and could be a potential adjuvant for vaccines against infectious diseases, especially in the mucosa.
has issue date	2015-09-01(xsd:dateTime)
bibo:doi	10.1155/2015/471468
bibo:pmid	26421290
has license	cc-by
sha1sum (hex)	9405b40aa26445cd02d7382bf256641ca774de46
schema:url	https://doi.org/10.1155/2015/471468
resource representing a document's title	Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus
has PubMed Central identifier	PMC4569761
has PubMed identifier	26421290
schema:publication	Biomed Res Int
resource representing a document's body	covid:9405b40aa26445cd02d7382bf256641ca774de46#body_text
is schema:about of	named entity 'nanoparticles' named entity 'nanoparticles' named entity 'antigen' named entity 'influences' named entity 'mucosal' named entity 'encapsulated' named entity 'Adjuvant' named entity 'PULLULAN' named entity 'NANOPARTICLES' named entity 'INFLUENZA VIRUS' named entity 'REPEATED ADMINISTRATION' named entity 'SAFETY STUDY' named entity 'LEADING' named entity 'COULD BE' named entity 'CAPABILITY' named entity 'ENCAPSULATED' named entity 'PRELIMINARY' named entity 'MUCOSA' named entity 'POTENTIAL' named entity 'DESCRIBE' named entity 'CELLULAR IMMUNITY' named entity 'ANTIGEN' named entity 'ACTIVATION' named entity 'ENHANCING' named entity 'VIRUS INFECTION' named entity 'TNF' named entity 'CONVENTIONAL' named entity 'VACCINES' named entity 'IGG' named entity 'HOST' named entity 'ADJUVANT' named entity 'DATA' named entity 'DENDRITIC CELLS' named entity 'NASOPHARYNX' named entity 'ENHANCE' named entity 'SLIGHT' named entity 'UPTAKE' named entity 'TOXICITY' named entity 'A MAJOR' named entity 'IMMUNE RESPONSES' named entity 'EFFECTIVE' named entity 'NANOPARTICLES' named entity 'LETHAL' named entity 'NASAL ROUTE OF ADMINISTRATION' named entity 'IMMUNOGENS' named entity 'STORAGE STABILITY' named entity 'SEVERE' named entity '2F8' named entity 'TO INVESTIGATE' named entity 'EXPRESSION' named entity 'COMBINED' named entity 'EXPERIMENTAL' named entity 'T CELLS' covid:arg/9405b40aa26445cd02d7382bf256641ca774de46 named entity 'TO PREPARE' named entity 'GENES' named entity 'OUR' named entity 'EFFECTIVE' named entity 'MUCOSAL VACCINE' named entity 'NASAL ADMINISTRATION' named entity 'MUCOSAL' named entity 'ENCAPSULATED' named entity 'MODERATELY' named entity 'INDUCED' named entity 'INDUCING' named entity 'RELATED' named entity 'REVERSIBLE' named entity 'CHOLESTERYL' named entity 'MODEL' named entity 'IMMUNE' named entity 'EXCELLENT' named entity 'TUMOR NECROSIS FACTOR' named entity 'CHALLENGE' named entity 'IGA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software